Intrexon Corp. (XON)

6.42
NASDAQ : Health Technology
Prev Close 6.25
Day Low/High 6.09 / 6.53
52 Wk Low/High 3.95 / 19.94
Avg Volume 1.47M
Exchange NASDAQ
Shares Outstanding 162.07M
Market Cap 1.01B
EPS -3.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Intrexon Reports Second Quarter And First Half 2019 Financial Results

Intrexon Reports Second Quarter And First Half 2019 Financial Results

- Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million -

Caution Is in the Air

Just days ago everyone was in the pool, and now so many are cautious -- but the statistics still show we're on track for overbought later in the week.

ActoBio Therapeutics™ Progresses AG019 To Next Stage Of A Phase Ib/IIa Clinical Study For The Treatment Of Type 1 Diabetes

ActoBio Therapeutics™ Progresses AG019 To Next Stage Of A Phase Ib/IIa Clinical Study For The Treatment Of Type 1 Diabetes

A unique approach based on specifically targeted and designed Lactococcus lactis AG019, aimed to prevent or reverse early-onset Type 1 Diabetes

First Week Of August 16th Options Trading For Intrexon (XON)

First Week Of August 16th Options Trading For Intrexon (XON)

Investors in Intrexon Corp saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XON options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Precigen Announces First Patient Dosed In Phase 1/1b Study Of PRGN-3006 UltraCAR-T™ In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Higher Risk Myelodysplastic Syndrome (MDS)

Precigen Announces First Patient Dosed In Phase 1/1b Study Of PRGN-3006 UltraCAR-T™ In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Higher Risk Myelodysplastic Syndrome (MDS)

- Milestone represents the first patient dosed with Precigen's transformative non-viral UltraCAR-T therapeutic platform that eliminates ex vivo expansion and reduces manufacturing time to fewer than two days following gene transfer

Change Is in the Air

It's not giddy yet, but we are certainly converting more and more former bears by the day.

Intrexon Corporation And Surterra Wellness Partner In $100mm Deal To Advance Commercial Scale Fermentation-based Cannabinoid Production

Intrexon Corporation And Surterra Wellness Partner In $100mm Deal To Advance Commercial Scale Fermentation-based Cannabinoid Production

Exclusive Global Agreement to Transform Surterra's Ability to Produce Specific Cannabinoids to Meet Growing Demand, Boost Innovation and Product Development

Intrexon's Subsidiary Precigen To Present At The JMP Securities Life Sciences Conference

Intrexon's Subsidiary Precigen To Present At The JMP Securities Life Sciences Conference

GERMANTOWN, Md., June 13, 2019 /PRNewswire/ --  Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned Intrexon Health subsidiary...

Oxitec Successfully Completes First Field Deployment Of 2nd Generation Friendly™ Aedes Aegypti Technology

Oxitec Successfully Completes First Field Deployment Of 2nd Generation Friendly™ Aedes Aegypti Technology

- First field trial achieved up to 96% suppression of target disease-transmitting mosquito populations in dense urban settings in Brazil

Intrexon Announces Advances In Non-Browning GreenVenus™ Romaine Lettuce

Intrexon Announces Advances In Non-Browning GreenVenus™ Romaine Lettuce

Non-Browning Romaine lettuce demonstrates improved shelf life, reducing food waste and is not subject to regulation as a product produced through genetic engineering by the USDA

Intrexon To Participate In 2019 BIO International Convention

Intrexon To Participate In 2019 BIO International Convention

GERMANTOWN, Md., May 28, 2019 /PRNewswire/ --   Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the Company and its subsidiaries will...

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

Uncertainty over the trade war's effects on earnings make this market really hard on investors, says Jim Cramer.

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Jim Cramer takes a look at Lululemon Athletica, Wayfair, Amazon, Intrexon, Iridium Communications, PayPal, Zscaler, Zynerba Pharmaceuticalsm and more.

Intrexon To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

Intrexon To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

GERMANTOWN, Md., May 13, 2019 /PRNewswire/ --  Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Randal J.

Intrexon Reports First Quarter 2019 Financial Results

Intrexon Reports First Quarter 2019 Financial Results

-- Quarterly GAAP revenues of $23.3 million and net loss attributable to Intrexon of $60.7 million including non-cash charges of $17.8 million --

Intrexon To Release First Quarter 2019 Financial Results On May 9th

Intrexon To Release First Quarter 2019 Financial Results On May 9th

GERMANTOWN, Md., May 2, 2019 /PRNewswire/ --   Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release first quarter 2019...

First Week Of June 21st Options Trading For Intrexon (XON)

First Week Of June 21st Options Trading For Intrexon (XON)

Investors in Intrexon Corp saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XON options chain for the new June 21st contracts and identified one put and one call contract of particular interest.

Intrexon And Xogenex Present At American Society Of Gene And Cell Therapy Annual Meeting

Intrexon And Xogenex Present At American Society Of Gene And Cell Therapy Annual Meeting

GERMANTOWN, Md., April 29, 2019 /PRNewswire/ --  Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its majority owned Intrexon Health subsidiary...

Precigen Opens Gene And Cell Therapy Manufacturing Facility In Germantown, Maryland

Precigen Opens Gene And Cell Therapy Manufacturing Facility In Germantown, Maryland

-Nearly 5,000 square foot facility will manufacture early stage clinical trial material for gene therapy trials

Oxitec Signs New Multi-year Development Agreement To Apply 2nd Generation Technology To Control Soybean Looper

Oxitec Signs New Multi-year Development Agreement To Apply 2nd Generation Technology To Control Soybean Looper

Oxitec to develop a safe, self-limiting insect capable of reducing pest populations and reversing insect resistance to biotech traits and chemistries

Intrexon To Highlight Microbial Cannabinoid Production Platform At The Paradigm Capital Biosynthesis Conference

Intrexon To Highlight Microbial Cannabinoid Production Platform At The Paradigm Capital Biosynthesis Conference

GERMANTOWN, Md., April 10, 2019 /PRNewswire/ --   Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Thomas D.

Oxitec Advances Self-Limiting Fall Armyworm Control Solution To Next Phase Of Development

Oxitec Advances Self-Limiting Fall Armyworm Control Solution To Next Phase Of Development

New collaboration agreement will advance scale-up and early field trials of Oxitec's self-limiting fall armyworm

Intrexon Intensifies Focus On Healthcare, Forms Two Units And Streamlines Management

Intrexon Intensifies Focus On Healthcare, Forms Two Units And Streamlines Management

- Move prompted by rapid progress at Intrexon's Precigen subsidiary -

First Week Of XON May 17th Options Trading

First Week Of XON May 17th Options Trading

Investors in Intrexon Corp saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XON options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Textbook Rally: Cramer's 'Mad Money' Recap (Monday 3/11/19)

Textbook Rally: Cramer's 'Mad Money' Recap (Monday 3/11/19)

Jim Cramer explains why rallies on a sentiment switch are often among the best.

Akamai, Twitter, CenturyLink: 'Mad Money' Lightning Round

Akamai, Twitter, CenturyLink: 'Mad Money' Lightning Round

Jim Cramer weighs in on Akamai, Twitter, CenturyLink, Fluidigm, Ambarella, Intrexon, Del Taco Restaurants, Orange and more.

TheStreet Quant Rating: D (Sell)